Clinical trial NCT01856218: An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)
Official title: An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of UX003 rhGUS Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Mucopolysaccharidosis Type 7
Keywords: Mucopolysaccharidosis type 7, MPS 7, Sly syndrome, enzyme replacement therapy, rare disease, lysosomal storage disease, metabolic disorder
Lead sponsor: Ultragenyx Pharmaceutical Inc
Sponsor class: INDUSTRY
First posted: 2013-05-17
Enrollment: 3
Sex: ALL
Minimum age (years): 5
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: UX003-CL201 is an open-label Phase 1/2 study to assess the safety, efficacy, and dose of UX003 in MPS 7 patients via intravenous (IV) administration every other week (QOW) for 36 weeks with up to an additional 36 weeks from the optional continuation period. Up to 5 participants, who are between 5 and 30 years of age inclusive, will be enrolled and treated with UX003.

The initial 12-week treatment period will be followed by a 24-week forced dose titration period to assess the optimal dose. Participants who complete both the initial treatment and forced dose titration periods will continue treatment in a 36- week continuation period.


Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of MPS 7 based on leukocyte or fibroblast glucuronidase enzyme assay or genetic testing confirming diagnosis.
* Elevated urinary glycosaminoglycan (uGAG) excretion at a minimum of 2-fold over normal.
* Between 5 and 30 years of age, inclusive (approximately 2 subjects between the ages of 20-30 years).
* Willing and able to provide written, signed informed consent, or in the case of subjects under the age of 18 (or 16 years, depending on the region), provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures.
* Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study.
* Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have had tubal ligation at least one year prior to Screening, or who have had total hysterectomy.

Exclusion Criteria:

* Has undergone a successful bone marrow or stem cell transplant or has any degree of detectable chimaerism with donor cells.
* Any known hypersensitivity to rhGUS or its excipients that, in the judgment of the Investigator, places the subject at increased risk for adverse effects.
* Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study.
* Use of any investigational product (drug or device or combination) within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments at any time during the study.
* Has a condition of such severity and acuity, in the opinion of the Investigator, that it warrants immediate surgical intervention or other treatment or may not allow safe study participation.
* Has a concurrent disease or condition that, in the view of the Investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or affect safety.

Primary outcomes:
measure: Percentage Change From Baseline in Urinary Glycosaminoglycan (uGAG) Dermatan Sulfate
timeFrame: Baseline, Week 14, Week 22, Week 30, Week 38, Week 72, and end of study (up to Week 132)
measure: Percentage Change From Baseline in uGAG Chondroitin Sulfate
timeFrame: Baseline, Week 14, Week 22, Week 30, Week 38, Week 72, and end of study (up to Week 132)
measure: Number of Participants With Any ≥ 50% Decrease in uGAG
timeFrame: up to Week 132
measure: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths, and Study/Treatment Discontinuations
timeFrame: Up to 242 weeks + 30 days. SAEs were recorded beginning at the time the subject signed the informed consent form through 30 days following the last study visit. Non-serious AEs were recorded from the time of informed consent through the last study visit.
Secondary outcomes:
measure: Acceptable Dose as Determined by Total uGAG Excretion Using a Forced Dose Titration Regimen
timeFrame: Week 36
measure: Change From Baseline at Week 36 in Six-Minute Walk Test (6MWT)
timeFrame: Baseline, Week 36
measure: Percent of Predicted Normal Distance Walked
timeFrame: 36 Weeks
measure: Change From Baseline at Week 36 in the 3-Minute Stair Climb Test (3MSCT)
timeFrame: Baseline, Week 36
measure: Change From Baseline at Week 36 in Pulmonary Function Testing (Spirometry)
timeFrame: Baseline, Week 36
measure: Change From Baseline at Week 36 in Growth Velocity for Height and Weight
timeFrame: Baseline, Week 36
measure: Change From Baseline at Week 36 in Shoulder Range of Motion (Goniometry)
timeFrame: Baseline, Week 36
Other outcomes:
Locations:
city: Manchester
country: United Kingdom
facility: Manchester Academic Health Science Centre
Study officials:
affiliation: Univeristy of Manchester
name: Simon Jones, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Qi Y, McKeever K, Taylor J, Haller C, Song W, Jones SA, Shi J. Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials. Clin Pharmacokinet. 2019 May;58(5):673-683. doi: 10.1007/s40262-018-0721-y.